Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

CONTEXT: Immune checkpoint inhibitors, including anti–programmed cell death-1 (PD-1) antibodies, have become promising treatments for a variety of advanced malignancies. However, these medicines can cause immune-related adverse events (irAEs), including endocrinopathies. OBJECTIVE: This study examin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Tomoko, Iwama, Shintaro, Yasuda, Yoshinori, Okada, Norio, Tsunekawa, Taku, Onoue, Takeshi, Takagi, Hiroshi, Hagiwara, Daisuke, Ito, Yoshihiro, Morishita, Yoshiaki, Goto, Motomitsu, Suga, Hidetaka, Banno, Ryoichi, Yokota, Kenji, Hase, Tetsunari, Morise, Masahiro, Hashimoto, Naozumi, Ando, Masahiko, Kiyoi, Hitoshi, Gotoh, Momokazu, Ando, Yuichi, Akiyama, Masashi, Hasegawa, Yoshinori, Arima, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2018
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836529/
https://www.ncbi.nlm.nih.gov/pubmed/29600292
http://dx.doi.org/10.1210/js.2017-00432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836529/
https://www.ncbi.nlm.nih.gov/pubmed/29600292
http://dx.doi.org/10.1210/js.2017-00432

Ejemplares similares